Keyphrases
Asian Population
100%
Episodic Migraine
100%
Chronic Migraine
100%
Dragon
100%
Erenumab
100%
Placebo
58%
Migraine
50%
Physical Function
50%
Diary
50%
Reverter
50%
Treatment Group
25%
Everyday Activities
25%
Physical Impairment
25%
Headache Days
16%
Migraine Disability Assessment
16%
Headache Impact Test-6 (HIT-6)
16%
Japan
8%
United States
8%
Clinical Characteristics
8%
Asian Countries
8%
China
8%
Confidence Interval
8%
Europe
8%
Assessment Score
8%
Odds Ratio
8%
Functional Impairment
8%
Monoclonal Antibody
8%
Body Mass Index
8%
Placebo Groups
8%
Demographic Characteristics
8%
Disease Duration
8%
Treatment Duration
8%
Efficacy Outcomes
8%
Phase III Clinical Trial
8%
Headache Frequency
8%
Medication Overuse
8%
Calcitonin Gene-related Peptide
8%
Disease Impact
8%
Activity Score
8%
Patient-reported Outcomes
8%
Migraine-related Disability
8%
Phase II Clinical Trial
8%
Medicine and Dentistry
Post-Hoc Analysis
100%
Transformed Migraine
100%
Episodic Migraine
100%
Revertant
100%
Erenumab
100%
Placebo
66%
Migraine
58%
Headache
41%
Physical Disease
25%
MIDAS (Migraine)
16%
Disease
8%
Clinical Trial
8%
Body Mass Index
8%
Prophylaxis
8%
Disease Duration
8%
Medication Overuse
8%
Functional Disease
8%
Patient-Reported Outcome
8%
Peptide Receptor
8%
Odds Ratio
8%
Pharmacology, Toxicology and Pharmaceutical Science
Transformed Migraine
100%
Episodic Migraine
100%
Erenumab
100%
Migraine
75%
Placebo
66%
Headache
41%
Physical Disease
25%
Disability
16%
Disease
8%
Clinical Trial
8%
Receptor
8%
Calcitonin
8%
Disease Duration
8%
Functional Disease
8%
Medication Overuse
8%
Human Monoclonal Antibody
8%
Neuroscience
Migraine
100%
Erenumab
100%
Placebo
28%
Headache
17%
Body Mass Index
3%
Calcitonin
3%
Medication Overuse
3%
Human Monoclonal Antibody
3%
Receptor
3%
Immunology and Microbiology
Revertant
100%
Erenumab
100%
Body Mass
8%
Human Monoclonal Antibody
8%